Read by QxMD icon Read

CV Disease

Rie Ernst, Jennifer Ogeer, Donald McCrann, Julie Cross, Marilyn Strong-Townsend, Hanne Friis, Michael Coyne, Celeste Clements, Corie Drake, Rachel Murphy
Kidney disease is common in companion animals, and traditionally diagnosed with serum creatinine concentration (sCr), blood urea nitrogen, and abnormal urinalysis findings. Symmetric dimethylarginine (SDMA) is a novel kidney biomarker that reflects glomerular filtration rate, increasing earlier than sCr with acute kidney injury and chronic kidney disease. This prospective study compared accuracy and precision of two commercial SDMA assays, the IDEXX SDMA Test and the DLD SDMA ELISA, relative to the established reference method, liquid chromatography/mass spectrometry (LC-MS)...
2018: PloS One
Lucía Ramos, Jorge Novo, Noelia Barreira, José Rouco, Manuel G Penedo, Marcos Ortega
Cardiovascular diseases (CVDs) are the leading cause of death throughout the world. The total risk of developing CVD is determined by the combined effect of different cardiovascular risk factors (e.g., diabetes, raised blood pressure, unhealthy diet, tobacco use, stress, etc.) that commonly coexist and act multiplicatively. Most CVDs can be prevented by an early identification of the highest risk factors and an appropriate treatment. The stratification of cardiovascular risk factors involves a wide range of parameters and tests that specialists use in their clinical practice...
September 26, 2018: Journal of Visualized Experiments: JoVE
Ming-Chun Chen, Ji-Hung Wang, Chung-Jen Lee, Bang-Gee Hsu
Purpose: Hyperleptinemia has been independently associated with human cardiovascular (CV) diseases. Accordingly, we evaluate the association between serum leptin and future CV events in patients with coronary artery disease (CAD). Patients and methods: This study enrolled 98 patients with CAD from January to December 2012. The primary endpoint included incidences of major adverse CV events and hospitalization. Patients follow-up had been completed on June 30, 2017...
2018: Therapeutics and Clinical Risk Management
Octavia Bane, Steven Peti, Mathilde Wagner, Stefanie Hectors, Hadrien Dyvorne, Michael Markl, Bachir Taouli
BACKGROUND: The test-retest/interobserver repeatability and diagnostic value of 4D flow MRI in liver disease is underreported. PURPOSE: To determine the reproducibility/repeatability of flow quantification in abdominal vessels using a spiral 4D flow MRI sequence; to assess the value of 4D flow parameters in diagnosing cirrhosis and degree of portal hypertension. STUDY TYPE: Prospective. SUBJECTS: Fifty-two patients with chronic liver disease...
October 14, 2018: Journal of Magnetic Resonance Imaging: JMRI
Panagiotis Anagnostis, Pavlos Siolos, Dimitrios Krikidis, Dimitrios G Goulis, John C Stevenson
BACKGROUND: Familial hypercholesterolaemia (FH) is a genetically determined lipid disorder, affecting 1 per 200-500 individuals in the general population. It is significantly and independently associated with increased risk of cardiovascular disease (CVD), although it remains still an underrecognized and undertreated disease. Lipoprotein (a) [Lp(a)] is a low-density-lipoprotein (LDL)-like molecule, containing an additional protein, apolipoprotein (a). OBJECTIVE: This review aims to present and discuss available data on the role of Lp(a) in patients with FH, in terms of its potential augmentation of CVD risk...
October 10, 2018: Current Pharmaceutical Design
Vasilios Papademetriou, Konstantinos Stavropoulos, Christodoulos Papadopoulos, Konstantinos Koutsampasopoulos, Kiriakos Dimitriadis, Kostas Tsioufis
BACKGROUND: Familial hypercholesterolemia (FH) is an inherited autosomal dominant disorder that is characterized by substantially increased low-density lipoprotein cholesterol (LDL-C) levels. Patients with FH have a significantly higher risk for cardiovascular (CV) events, and the timely reduction of LDL-C is of paramount importance to ameliorate the risk for CV disease. Among the available lipid-lowering therapies, the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as a very promising class of drugs for the management of such patients...
October 10, 2018: Current Pharmaceutical Design
Manuel Almendro-Delia, Iván J Núñez-Gil, Manuel Lobo, Mireia Andrés, Oscar Vedia, Alessandro Sionis, Ana Martin-García, María Cruz Aguilera, Eduardo Pereyra, Irene Martín de Miguel, José A Linares Vicente, Miguel Corbí-Pascual, Xavier Bosch, Oscar Fabregat Andrés, Alejandro Sánchez Grande Flecha, Alberto Pérez-Castellanos, Javier López Pais, Manuel De Mora Martín, Juan María Escudier Villa, Roberto Martín Asenjo, Marta Guillen Marzo, Ferrán Rueda Sobella, Álvaro Aceña, José María García Acuña, Juan C García-Rubira
OBJECTIVES: This study sought to describe the incidence, determinants, and prognostic impact of cardiogenic shock (CS) in takotsubo syndrome (TTS). BACKGROUND: TTS can be associated with severe hemodynamic instability. The prognostic implication of CS has not been well characterized in large studies of TTS. METHODS: We analyzed patients with a definitive TTS diagnosis (modified Mayo criteria) who were recruited for the National RETAKO (Registry on Takotsubo Syndrome) trial from 2003 to 2016...
October 4, 2018: JACC. Heart Failure
Yusong Jiang, Mengjun Huang, Meixia Zhang, Jianbi Lan, Weixun Wang, Xiang Tao, Yiqing Liu
Ginger (Zingiber officinale Roscoe), one of the most economically valuable plants in the Zingiberaceae family, is widely used as a spice and flavoring agent for beverages, bakery, confectionary, and pharmaceutics. Bacterial wilt disease, caused by Ralstonia solanacearum, is one of the most detrimental production constraints in ginger cultivation. Field cultivation experiments indicated that soil moisture affects the incidence of bacterial wilt disease. However, the relationship between soil moisture and bacterial wilt incidence as well as the mechanism that underlie this infection remain unclear...
October 9, 2018: Plant Physiology and Biochemistry: PPB
Barbara Baldo, Muhammad Umar Sajjad, Rachel Y Cheong, Julie Bigarreau, Ravi Vijayvargia, Catriona McLean, Anselme L Perrier, Ihn Sik Seong, Glenda Halliday, Åsa Petersén, Deniz Kirik
The neurodegenerative Huntington's disease (HD) is caused by a polyglutamine (polyQ) amplification in the huntingtin protein (HTT). Currently there is no effective therapy available for HD; however, several efforts are directed to develop and optimize HTT-lowering methods to improve HD phenotypes. To validate these approaches, there is an immediate need for reliable, sensitive, and easily accessible methods to quantify HTT expression. Using the AlphaLISA platform, we developed two novel sensitive and robust assays for quantification of HTT in biological samples using commercially available antibodies...
July 2018: ENeuro
Fabrizio Fabrizi, Piergiorgio Messa
Hepatitis C virus (HCV) infection leads to important morbidity and mortality through liver disease and extra-hepatic manifestations. Recent evidence suggests the role of HCV in developing chronic kidney disease (CKD); also, HCV adversely affects cardiovascular (CV) disease both in the general population and in patients with CKD. Areas covered: All-oral, interferon-free direct-acting antiviral agents (DAAs) are currently available; anti-HCV regimens based on DAAs are provided with high efficacy and safety and short treatment duration...
October 12, 2018: Expert Review of Clinical Pharmacology
Sang-Woong Choi, Hyungseop Kim, In-Cheol Kim, Cheol-Hyun Lee, Jongmin Hwang, Hyoung-Seob Park, Yun-Kyeong Cho, Hyuck-Jun Yoon, Chang-Wook Nam, Seongwook Han, Seung-Ho Hur
PURPOSE: Ultrasonographic contrast enhancement of carotid plaque (CECP) has been used to detect neovascularization of vasa vasorum and plaque. However, it is uncertain whether CECP can provide risk stratification of coronary artery disease (CAD). This study aimed to evaluate the relationship between CECP and manifestations of acute coronary syndrome (ACS) in established CAD patients and to explore the prognostic implication of CECP for cardiovascular (CV) clinical outcomes. METHODS: A medical record review revealed that contrast-enhanced ultrasonography was performed to evaluate carotid atherosclerosis in 209 coronary artery-stented and 105 non-stented patients...
September 2018: Journal of Clinical Ultrasound: JCU
Lingling Xu, Xiaopu Lin, Meiping Guan, Yingshan Liu
INTRODUCTION: Early detection of diabetic peripheral neuropathy (DPN) is critical in patients with type 2 diabetes mellitus (T2DM) due to the lack of targeted therapy for DPN. We have investigated the relationship between different stages of diabetic nephropathy and DPN in an attempt to elucidate whether albuminuria can be used as an early warning signal of DPN progression. METHODS: A total of 217 T2DM patients who met the inclusion criteria were recruited from the Department of Endocrinology, Nanfang Hospital between January 2016 and June 2016...
October 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
J Jackowska, H Klimza, P Winiarski, K Piersiala, M Wierzbicka
OBJECTIVES/HYPOTHESIS: Recurrent respiratory papillomatosis (RRP) is a benign disease caused by human papillomavirus 6 and 11. The characteristic feature of this disease are wart-like lesions covering the respiratory epithelium with a predilection for the larynx. There is no curative treatment for the disease. The goal of the treatment is a total surgical removal of the papillomatous lesions in order to reduce the number of relapses. Therefore, a good visualization method of papillomas is crucial during surgery...
2018: PloS One
Emanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, Fabrizio De Ponti, Giulio Marchesini
Pharmacotherapy used to treat type 2 diabetes mellitus (T2DM) is facing a paradigm shift in clinical practice with recent cardiovascular (CV) outcome trials having a substantial impact on drug prescription with treatment having a more tailored approach. In patients with T2DM, the issue of chronic liver disease is multifaceted. However, a clinical evidence is emerging on the beneficial effect of antidiabetic medications on nonalcoholic fatty liver disease (NAFLD). Areas covered: The authors provide a synopsis on the current and upcoming pharmacotherapy for NAFLD, including the challenges with their development, focusing on drugs for T2DM...
October 9, 2018: Expert Opinion on Pharmacotherapy
Adiel Roitman, Ilan Ben-Zvi, Liran Mendel, Avi Livneh
OBJECTIVES: Patients, suffering from inflammatory disorders, are at an increased risk to develop cardiovascular disease (CVD). Here, we examine whether in familial Mediterranean fever (FMF), a model of inflammatory diseases, inflammation also increases the risk to develop cardiovascular (CV) disease. METHODS: To explore the role of inflammation in the occurrence of CVD in FMF, we identified all FMF patients ≤55 years old with CVD, admitted to our center over a 15-year period...
September 27, 2018: Clinical and Experimental Rheumatology
Anna Maria Ansaldo, Fabrizio Montecucco, Amirhossein Sahebkar, Franco Dallegri, Federico Carbone
Obesity is a heterogeneous disease with different degrees of cardiovascular (CV) and metabolic manifestations. Certain ectopic fat depots may contribute to obesity-related CV risk and may explain part of the risk differential observed in metabolically healthy obese and the so called "obesity paradox". The growing interest towards the potential impact of epicardial adipose tissue (EAT) in cardiovascular (CV) risk has led to deepen its biological function. Genetic, epigenetic and environmental factors may drive the shift towards a dysfunctional EAT characterized by a pro-inflammatory and pro-fibrotic phenotype...
October 1, 2018: International Journal of Cardiology
Hyon Choi, Tuhina Neogi, Lisa Stamp, Nicola Dalbeth, Robert Terkeltaub
We appreciate Dr. Kuwabara's sharing FEATHER study data in relation to our article2 about the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial. As pointed out, we agree that the FEATHER study's overall cardiovascular (CV) disease outcome results4 tended to be consistent with the CARES trial findings, although its sample size was >10 time smaller than the CARES trial and underpowered for that purpose. The author states no difference of CV mortality, but no data are provided, although the number of CV deaths would be less than the overall CV event rates (4/219 in febuxostat and 7/222 in placebo)...
October 8, 2018: Arthritis & Rheumatology
Danilo Iannetta, Erin Calaine Inglis, Rogerio N Soares, Kaitlin M McLay, Silvia Pogliaghi, Juan M Murias
BACKGROUND: Cardiovascular disease (CVD) is associated with impairments in microvascular responsiveness. Therefore, reliably assessing microvascular function is clinically relevant. Thus, this study aimed to examine the reliability of the near-infrared spectroscopy (NIRS)-derived oxygen saturation (StO2 ) reperfusion slope, a measure of microvascular responsiveness, to four different vascular occlusion tests (VOT) of different durations in young and older participants. METHODS: Eight healthy young (29 ± 5 yr) and seven older (67 ± 4 yr) men participated in four NIRS combined with VOT (NIRS-VOT; 30 s, 1, 3, and 5 min) in the leg microvasculature on two visits separated by 1-2 weeks...
October 4, 2018: Microvascular Research
Jing-Wei Li, Min-Rui Wang, Hai-Yan Chen, Lei Zhao, Zhen-Hua Cui, Zhibo Zhang, Dag-Ragnar Blystad, Qiao-Chun Wang
Availability of and easy access to diverse plant viruses and viroids is a prerequisite in applied and basic studies related to viruses and viroids. Long-term preservation of viruses and viroids is difficult. A protocol was described for long-term preservation of potato leafroll virus (PLRV), potato virus S (PVS), and potato spindle tuber viroid (PSTVd) in cryopreserved shoot tips of potato cv. Zihuabai. Shoot regrowth levels following cryopreservation were higher in 1.5 mm-shoot tips (58-60%) than in 0.5-mm-ones (30-38%)...
October 6, 2018: Applied Microbiology and Biotechnology
Christopher P Cannon, Darren K McGuire, Richard Pratley, Sam Dagogo-Jack, James Mancuso, Susan Huyck, Bernard Charbonnel, Weichung J Shih, Silvina Gallo, Urszula Masiukiewicz, Gregory Golm, Francesco Cosentino, Brett Lauring, Steven G Terra
BACKGROUND: Ertugliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), approved in the United States and European Union to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). The VERTIS cardiovascular (CV) outcomes trial (NCT01986881) has a primary objective to demonstrate non-inferiority of ertugliflozin versus placebo on major adverse CV events: time to the first event of CV death, nonfatal myocardial infarction, or nonfatal stroke. Secondary objectives are to demonstrate superiority of ertugliflozin versus placebo on time to: 1) the composite outcome of CV death or hospitalization for heart failure (HF); 2) CV death; and 3) the composite outcome of renal death, dialysis/transplant, or doubling of serum creatinine from baseline...
September 5, 2018: American Heart Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"